Alamar Biosciences (ALMR): Down From the Peak, Still Above the Offering
Alamar’s proteomics growth remains strong, but a sharp pullback has reset expectations. Investors now face a premium valuation, continued losses...
23 Views
Kailera Therapeutics (KLRA): Post-180-Day Review: Heavyweight Backers, Lightweight Returns
KLRA's 62.5% IPO opening premium has vanished, with shares 33% below issue. Phase 3 enrollment is complete, but investor patience and aftermarket...
20 Views
Madison Air Solutions (MAIR): Post 180-Days: Strong Fundamentals, Deflating Shares
Madison Air (MAIR) shares have fallen below IPO price despite higher guidance, strong backlog growth and a transformative acquisition that expands...
45 Views
Arxis (ARXS): Post 180 Days; Acquisition Engine Keeps Firing as IPO Gains Endure
Arxis is riding aerospace and defense tailwinds, acquisition-driven growth and expanding margins. Up 71% from its IPO price, the company could have...
42 Views
Iambic Therapeutics Inc. (IAM): Bringing an AI Twist to the Biotech IPO Market
Iambic Therapeutics pairs AI-driven drug discovery with automated labs and a clinical-stage oncology pipeline. Strong reported demand and high...
53 Views